Kim YH, et al. - In ST-segment elevation myocardial infarction (STEMI) patients with multivessel coronary artery disease (MVD) who underwent two different reperfusion strategies, researchers compared 1-year clinical outcomes between biodegradable-polymer (BP)-coated biolimus-eluting stent (BES) and durable-polymer (DP)-coated drug-eluting stent (DES). A total of 2,571 patients were included in a culprit-only group (BP- [n=264] or DP-DES [n=2,307]) and 1,684 were included in a multivessel percutaneous coronary intervention group (BP- [n=145] or DP-DES [n=1,539]). For major adverse cardiac events and stent thrombosis, the 1-year adjusted hazard ratio was comparable between BP-BES and DP-DES. During a 1-year follow-up, the observed safety and efficacy of BP-BES and DP-DES were comparable in this patient population.